

**Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using  
a Prodrug Strategy: *In Vivo* Pharmacology of LY544344**

Linda M. Rorick-Kehn, Everett J. Perkins, Karen M. Knitowski, John C. Hart,  
Bryan G. Johnson, Darryle D. Schoepp, David L. McKinzie

Neuroscience Discovery Research, Eli Lilly and Company  
Indianapolis, IN 46285 USA

**Running Title:** Improved bioavailability using mGlu2/3 prodrug LY544344

**Number of Text Pages:** 18

**Number of Tables:** 2

**Number of Figures:** 4

**Number of References:** 32

**Number of Words in Abstract:** 250

**Number of Words in Introduction:** 750

**Number of Words in Discussion:** 1496

### **Abbreviations**

AMPA =  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANOVA = analysis of variance;  
CNS = central nervous system; CS = conditioned stimulus; iGlu = ionotropic glutamate receptor;  
mGlu = metabotropic glutamate receptor; NMDA = *N*-methyl-*D*-aspartate; PCP = phencyclidine

### **Corresponding author:**

Dr. David McKinzie  
Neuroscience Discovery Research  
Eli Lilly and Company  
Lilly Corporate Center, DC0510  
Indianapolis, IN 46285 USA  
Tel: 317-433-4327  
Fax: 317-276-5546  
Email: [dmckinzie@lilly.com](mailto:dmckinzie@lilly.com)

**JPET Section:** Neuropharmacology

## Abstract

Numerous studies have indicated that selective agonists of group II metabotropic glutamate (mGlu) receptors, such as LY354740 and LY379268, may be useful in the treatment of many psychiatric disorders, including psychosis, anxiety, and drug withdrawal. Although animal and human studies demonstrate potential therapeutic utility, poor oral bioavailability is a limiting factor in the clinical development of these compounds. Therefore, a novel prodrug approach is being pursued in order to increase exposure levels of active compound following oral administration. Here, we demonstrate a 10-fold increase in brain, plasma, and CSF levels of LY354740 following oral prodrug administration. Further, we compare the oral efficacy of the mGlu2/3 receptor agonist LY354740 and its prodrug (LY544344) in rodent models of psychosis and anxiety. Phencyclidine (PCP)-induced hyperlocomotion was dose-dependently inhibited in rats receiving oral administration of 30 or 100 mg/kg LY544344, whereas LY354740 did not significantly reverse PCP-mediated behaviors at doses up to 100 mg/kg. Orally administered LY544344 (30 mg/kg) and subcutaneously administered LY354740 (10 mg/kg) attenuated stress-induced hyperthermia in DBA/2 mice, with the prodrug producing anxiolytic effects at lower oral doses than the parent compound. Although oral administration of LY354740 did not significantly affect fear-induced suppression of operant responding in rats, subcutaneously administered LY354740 (10 or 20 mg/kg) and orally administered LY544344 (10 or 30 mg/kg) produced significant anxiolytic effects in this model. The present data confirm that mGlu2/3 receptor agonists produce antipsychotic and anxiolytic effects in animal behavioral models and demonstrate that oral bioavailability of LY354740 was substantially increased using a prodrug strategy.

## Introduction

Glutamate is the primary excitatory neurotransmitter in the brain. Ionotropic glutamate (iGlu) receptors are ligand-gated ion channels that mediate fast synaptic excitatory neurotransmission via NMDA, AMPA, and kainate receptors (Feldman et al., 1997). In contrast, metabotropic glutamate (mGlu) receptors are G-protein-coupled receptors that appear to have evolved to modulate neuronal excitability (Feldman et al., 1997; Schoepp, 2001). Numerous studies indicate that many neurological and psychiatric disorders may be linked to excessive neuronal excitability, including psychosis, anxiety, drug dependence, ischemia, and epileptic seizures (Baptista et al., 2004; Bergink et al., 2004; Moghaddam, 2002; Parsons et al., 1998; Vandergriff and Rasmussen, 1999). Because mGlu receptors are linked to modulatory second messenger systems, pharmacological manipulation of these receptors may reduce excessive glutamatergic excitatory activation without affecting global CNS functionality or producing unwanted side effects, as have been observed with NMDA antagonists and benzodiazepines (Cartmell et al., 1999; Gudex, 1991; Moghaddam and Adams, 1998; Schoepp and Marek, 2002). The emergence of mGlu receptor subtype-selective compounds with agonist and antagonist properties suggests that they may be promising therapeutic targets for the treatment of many psychiatric disorders (Schoepp et al., 1999).

There are currently eight known mGlu receptor subtypes, which can be divided into three classes based on structural sequence homology, receptor coupling, and pharmacology. Group I mGlu receptors (mGlu1, mGlu5) are coupled to phosphoinositide hydrolysis, while group II (mGlu2, mGlu3) and group III (mGlu4,6,7,8) receptors are negatively coupled to cyclic AMP production (Schoepp et al., 1999). Group II mGlu2/3 receptors are localized primarily in limbic and forebrain regions, such as the frontal cortex, hippocampus, amygdala, and locus coeruleus (Dube and Marshall, 1997; Ohishi et al., 1993a,b). This pattern of localization suggests that mGlu2/3 receptors may be important targets for pharmacological treatment of such disorders as anxiety and psychosis (Moghaddam, 2002; Schoepp, 2001; Swanson et al., 2005). Thus,

precise manipulation of specific receptor subtypes in restricted brain areas may allow for more direct therapeutic intervention of psychiatric disorders as well as reduced propensity for side effects.

Although located in both pre- and post-synaptic sites, mGlu2/3 receptors function primarily as presynaptic autoreceptors (Cartmell and Schoepp, 2000; Dube and Marshall, 1997). Activation of these receptors by selective mGlu2/3 agonists, such as LY354740 and LY379268, dampens glutamate hyperexcitability by reducing its presynaptic release in the prefrontal cortex and locus coeruleus (structure of LY354740 shown in Table 1; Moghaddam and Adams, 1998; Homayoun et al., 2005; Vandergriff and Rasmussen, 1999). mGlu2/3 agonists, including LY354740, have demonstrated efficacy in animal behavioral models of anxiety, psychosis, and drug withdrawal. For example, studies in rats have demonstrated that LY354740 decreased fear-potentiated startle responses, increased open arm time in the elevated plus-maze, increased the number of punished responses in conflict tests, and reversed behavioral and psychotomimetic actions of NMDA antagonists such as phencyclidine (PCP) and MK-801 (Helton et al., 1998; Homayoun et al., 2005; Klodzinska et al., 1999; Moghaddam and Adams, 1998; Schoepp et al., 1999; Schoepp and Marek, 2002; Tizzano et al., 2002; Vandergriff and Rasmussen, 1997). Similarly, LY354740 exerted an anxiolytic-like effect in a test of fear-potentiated startle in humans (Grillon et al., 2003). A possible role for LY354740 in drug dependence was supported by electrophysiological and behavioral evidence of attenuation of morphine-withdrawal in rats (Klodzinska et al., 1999; Vandergriff and Rasmussen, 1997). Unlike GABAergic agonists, LY354740 produced these behavioral effects at doses that did not produce sedation or impair motor performance or cognitive function (Cartmell et al., 1999; Helton et al., 1998; Klodzinska et al., 1999).

Although animal and human studies demonstrate the potential therapeutic utility of mGlu2/3 agonists in several models of psychiatric/clinical disorders, low levels (~10%) of LY354740 are absorbed following oral administration, thus requiring larger doses in clinical

populations (Johnson et al., 2002). Therefore, a prodrug approach is being pursued to obtain an mGlu2/3 agonist with acceptable oral bioavailability. Instead of relying on passive diffusion through the intestinal epithelium, the prodrug LY544344 is actively transported out of the intestinal tract via the peptide transporter PepT1. Once transported from the intestinal tract into the central nervous system (CNS), enzymatic processes metabolize LY544344 into the active mGlu2/3 receptor agonist LY354740. Using this approach, 85% oral bioavailability has been achieved in animal studies (Bueno et al., 2005).

The present experiments were conducted to directly compare the oral efficacy of the mGlu2/3 receptor agonist LY354740 and its prodrug LY544344 in animal models of psychosis and anxiety, including reversal of PCP-induced hyperlocomotion, stress-induced hyperthermia, and fear-induced suppression of operant behavior (Cartmell et al., 1999; Rorick-Kehn et al., in press; Stanhope and Dourish, 1996).

## Methods

### Animals

Male Sprague-Dawley rats weighing approximately 250 – 350 g (Harlan Sprague Dawley Inc., Indianapolis, IN) were tested in the PCP-induced hyperlocomotion and fear-induced suppression of operant responding experiments. Rats were pair-housed with water available *ad libitum*, and maintained on a 12 h light/dark cycle (lights on at 06:00). A total of 48 rats were used to assess the effects of LY354740 and LY544344 on spontaneous locomotor activity. A total of 25 rats were used in the PCP-induced hyperlocomotion experiment (LY354740, n = 9; LY544344, n = 16). For these experiments, rats were food-fasted for 12 to 18 hours prior to the experiment. For the operant tests, a total of three different groups of rats were used. An initial test using subcutaneous administration of LY354740 was conducted (n = 7), followed by a second experiment using LY354740 (n = 14), and a third experiment using LY544344 (n = 14). For the second LY354740 experiment, oral and subcutaneous dose-response assessments were measured in the same group of 14 rats, with one week between experiments. Therefore, some of the rats used in these experiments had previous drug exposure. Rats were maintained at 85% of their free-feeding weights for the duration of each experiment. Stress-induced hyperthermia experiments were conducted using male DBA/2 mice (n = 6-8/group) weighing approximately 25 – 35 g (Taconic, Germantown, NY). For these experiments, one week elapsed between testing of subsequent compounds. All mice were individually housed, with food and water available *ad libitum*, and maintained on a 12 h light/dark cycle (lights on at 06:00). All experiments were conducted in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals (Publication No. 85-23) and were approved by the Eli Lilly Institutional Animal Care and Use Committee.

### Surgical Procedures

Radiotelemetric analysis of stress-induced hyperthermia in DBA/2 mice required the implantation of small radiotransmitters approximately one week prior to experimental

procedures. All surgical procedures were performed under aseptic conditions. Mice were anesthetized using a 1.5% concentration of isoflurane and shaved along the ventrum. A 1.5 cm incision was made through the skin and abdominal wall along the midline, through which a sterile radiotelemetric transmitter (Data Sciences International, Arden Hills, MN) was implanted into the peritoneal cavity. The abdominal wall and skin were then sutured and mice were returned to the home cage for recovery. Following surgery, animals were administered 0.05 mg/kg buprenorphine (s.c.), individually housed, and allowed five to seven days to recover from surgery.

### **Drugs**

Phencyclidine (PCP) was obtained from Sigma Aldrich (St. Louis, MO). LY354740 and LY544344-HCl (LY544344) were synthesized at Lilly Research Laboratories. LY354740 was solubilized in sterile water by the drop-wise addition of NaOH, while LY544344 and PCP were dissolved in sterile water. Sterile water was administered to vehicle groups. All drugs were mixed fresh prior to use and administered orally, unless otherwise stated. Mice were dosed with a volume of 10 ml/kg. Rats were dosed with a volume of 1 ml/kg, unless otherwise stated.

### **Pharmacokinetics of LY354740: Oral Administration of LY354740 or LY544344**

Male Sprague-Dawley rats weighing approximately 330 - 375 g (Harlan Sprague Dawley Inc., Indianapolis, IN) were given a single oral dose of LY544344-HCl (10 mg/kg) or LY354740 monohydrate (100 mg/kg). Doses were administered by oral gavage in aqueous solution (5 ml/kg). Plasma, cerebrospinal fluid (CSF) and brain samples were collected following euthanasia from 3 rats/group at 0.5, 3, 12, 24, 48, 72, 96, 120, 144, and 168 hours after dosing. Whole blood samples were collected by cardiac puncture into tubes containing EDTA at each time point, and plasma was obtained by centrifugation. CSF was collected from the cisterna magna, and whole brains were collected after whole-body perfusion with 45 ml of isotonic



saline. Plasma, CSF and brain samples were stored at approximately  $-70^{\circ}\text{C}$  until analysis.

Rats were euthanized by  $\text{CO}_2$  fixation during the terminal blood collection.

Concentrations of LY354740 were determined by LC/MS/MS. LY354740 was extracted from either 150  $\mu\text{l}$  of plasma or 50  $\mu\text{l}$  of CSF by cation exchange solid phase extraction. Whole brains were homogenized in purified water (2 ml  $\text{H}_2\text{O}$ / g of brain). LY354740 was extracted from 300  $\mu\text{l}$  (0.1 g) of brain homogenate by protein precipitation, followed by cation exchange SPE, followed by anion exchange SPE. Samples were chromatographically separated using a Restek Ultra IBD column (2.1 mm x 100 mm; 3  $\mu\text{m}$ ) with a water/methanol/acetic acid (90/10/0.2, v/v) mobile phase at approximately  $50^{\circ}\text{C}$ . The flow rate was 0.3 ml/minute. LY354740 were detected using selective reaction monitoring/ESI/TurboIonSpray on a PE-Sciex API 3000 instrument.

Pharmacokinetic parameters were calculated using noncompartmental analysis with WinNonlin v.3.1 (Pharsight Corporation, Mountain View, CA). Concentrations of LY354740 (brain, plasma, and CSF) below the lower limit of quantification (10 ng/g for brain, 5 ng/ml for plasma, and 1 ng/ml for CSF) were assigned a value of zero for calculation purposes.

### ***Spontaneous Locomotor Activity and PCP-Induced Hyperlocomotion***

Behavioral parameters of spontaneous locomotor activity and PCP-induced hyperlocomotion were monitored in transparent cages (45 x 20 x 20 cm; Ancare, Bellmore, NY) containing a thin layer of wood chips (1 cm) on the cage floor and a metal grill on top of the cage. Rectangular photocell monitors (Hamilton Kinder, Poway, CA) were placed around each test cage during the experiment. One grid of 12 photocell beams arranged in an 8 x 4 configuration was positioned 5 cm above the cage floor to enable detection of body movements (ambulations) and head movements, while another grid positioned 15 cm above the cage floor detected rearing activity. Ambulations, head movements, and rearing were recorded by a computer for offline analysis.

To assess the effects of LY354740 and LY544344 on spontaneous locomotor activity, animals received an oral gavage of vehicle (sterile water, 1 ml/kg) or test compound (100 mg/kg LY354740; or 3, 10, 30, or 100 mg/kg LY544344) and returned to their homecage. After 60 min, rats were placed in the test cage for a 90 min assessment of spontaneous locomotor activity.

On the test day, rats were administered a randomly assigned dose of LY354740 (10, 30, or 100 mg/kg), LY544344 (3, 10, 30, or 100 mg/kg), or sterile water vehicle (1 ml/kg), and returned to their homecage for 30 min. Rats were then placed in the test cage for a 30 min habituation period to allow for acclimation to the test cage environment and to measure baseline locomotor activity. Following the habituation period, animals were administered a challenge dose of PCP (5 mg/kg, s.c.) or 0.9% NaCl vehicle (1 ml/kg, s.c.) and returned to the test cage for an additional 60 min, during which stimulant-induced behavioral activity was recorded.

### ***Stress-Induced Hyperthermia in DBA/2 Mice***

Mice were administered a randomly assigned dose of LY354740 (3, 10, or 30 mg/kg), LY544344 (3, 10, or 30 mg/kg), or vehicle (sterile water, 10 ml/kg). Mice were then returned to their home cages and each cage was placed onto a receiver configured to the specifications of each transmitter, which relayed core body temperature ( $^{\circ}$  C) measurements to the computer once every five min. Following placement on the receiver, the lights were turned off and the experimenter left the room for a 60 min baseline assessment period. Following the baseline period, the lights were turned on and mice were removed from their home cage and placed in a novel cage (Ancare; 20 cm X 20 cm X 29 cm) containing soiled shavings and feces from a rat cage (approximately 5 cm depth). Body temperature was recorded in 5-min increments for an additional 60 min. For comparison purposes, an additional experiment was conducted in which mice received an s.c. injection of either vehicle (0.9% NaCl) or LY354740 (10 mg/kg). These experiments replicate the results of a previous stress-induced hyperthermia experiment using LY354740 (Rorick-Kehn et al., in press).

### ***Fear-Induced Suppression of Operant Behavior***

Operant conditioning was monitored in standard operant boxes (Coulbourn Instruments, Allentown, PA) consisting of two stainless steel and two Plexiglas walls. The grid floor was comprised of stainless steel bars, 0.5 cm in diameter located approximately 1.5 cm apart (center to center). An operant lever was positioned in the middle of one stainless steel wall, approximately 10 cm above the floor grid.

Food-restricted rats were first trained to lever press for food reward (45 mg sucrose pellets; BioServ, Frenchtown, NJ), on a variable interval (VI)-30 s ( $\pm$  10 s) schedule of reinforcement during daily 32 min sessions. Once a stable level of responding was reached (approximately 2 – 3 weeks), rats were transferred to fear-suppressed operant conditioning. During this phase of the experiment, rats received daily 32-min sessions consisting of two trials. Each trial consisted of a 10-min baseline period, during which no stimuli were presented, followed by a 2-min conditioned stimulus (CS) period, during which a 5-watt houselight was illuminated. During the last 0.5 s of the CS period, rats received a 0.3 mA co-terminating footshock. Thus, the CS signaled the impending inescapable footshock. Each session ended after an additional baseline period following the second trial. Throughout the session, lever presses made by the animal were reinforced on a VI-30 s schedule. On test days in the first experiment, rats received subcutaneous administration of vehicle (0.9% NaCl, 2 ml/kg) or LY354740 (5, 10, or 20 mg/kg, 2 ml/kg) 30 min prior to the session, in a within-subject, ascending dose-response design. In later experiments, rats were orally administered a dose of LY354740 (10 or 30 mg/kg, in a volume of 2 ml/kg), LY544344 (3, 10, or 30 mg/kg), or sterile water vehicle (2 ml/kg or 1 ml/kg, respectively), 60 min prior to the test session, using ascending doses in a within-subject design. For comparison purposes, an additional experiment was conducted in which rats received either vehicle (0.9% NaCl, s.c. administration, 30-min pretreatment time) or LY354740 (10 mg/kg, s.c.). At least 3 days elapsed between doses of each experimental drug and, in the second LY354740 experiment, one week elapsed between

subsequent dose-response assessments. Behavioral measures recorded were the number of operant responses made during the 2 min CS period, the number of operant responses made during the last 2 min of the baseline period, and the suppression ratio [CS responses / (CS responses + Baseline responses)].

### **Statistics**

In the spontaneous locomotor activity test, a repeated measures analysis of variance (ANOVA) was calculated for the first 30 min of the behavioral assessment, with Dose as the between-subject factor and Time as the within-subject repeated measure. Significant ANOVAs were followed by one-way ANOVAs at each timepoint and a Dunnett's post-hoc comparison. In the PCP-induced hyperlocomotion test, data were analyzed for each compound using one-way ANOVA, with Dose as a between-subject factor. For the stress-induced hyperthermia test, a one-way ANOVA was calculated on the pre-stress baseline body temperatures and a mixed-design ANOVA was calculated on the difference scores (post-stress – pre-stress body temperature) during the 60-min stress period, with time as the within-subject factor. For fear-induced suppression of operant responding, data for each experimental compound were analyzed using one-way ANOVA, with Dose as the within-subject factor. Significant ANOVAs were followed by post-hoc comparisons using the Dunnett's t-test ( $\alpha = 0.05$ ). In the PCP-induced hyperlocomotion test, post-hoc Dunnett's t-tests were conducted using both the veh/veh and veh/PCP groups as the control group.

## Results

### ***Pharmacokinetic Properties of LY354740: Oral Administration of LY354740 or LY544344***

The chemical structures and mean pharmacokinetic parameters of the mGlu2/3 receptor agonist LY354740 following oral administration of LY354740 or the prodrug LY544344 are reported in Table 1. LY544344 was rapidly absorbed and converted to LY354740 following oral administration, leading to a marked increase in relative systemic availability of LY354740. The rate of increase in LY354740 concentrations was faster in the LY544344-dosed group, consistent with rapid intestinal absorption of LY544344 via active PepT1-mediated transport. Initial uptake of LY354740 into the brain was similarly rapid, but a lag period of at least several hours existed between the peak concentrations in plasma and brain. However, the true lag time between plasma and brain peaks is difficult to determine based on the current sampling schedule. Despite the rapid appearance of LY354740 in the CNS, concentrations were relatively low in brain and CSF compared to plasma, indicating limited passive penetration of LY354740 through the blood-brain barrier and blood–CSF barrier (Figure 1). In both dose groups, plasma exposure to LY354740 (AUC) was approximately 4-fold higher than brain and 50 – 70-fold higher than CSF. The similarity of CNS exposure at similar plasma concentrations indicates that the prodrug itself does not have any direct contribution to brain penetration of LY354740 at efficacious doses.

The elimination profiles of LY354740 in plasma and brain were characterized by a single compartment, with elimination half-lives ( $t_{1/2}$ ) ranging from approximately 4 hours to 74 hours, respectively. In contrast, the elimination of LY354740 in CSF displayed multiple phases, mirroring plasma concentrations at early time points and elimination from brain tissue at later times (Figure 1). Although CSF and brain concentrations appear to be at equilibrium beyond 48 hours, the substantially lower concentrations in CSF suggest a sequestering of LY354740 within the brain tissue. The underlying cause of prolonged brain retention and the sites of brain deposition in rats have not been fully elucidated.

### ***Spontaneous Locomotor Activity and PCP-Induced Hyperlocomotion***

Baseline locomotor activity decreased throughout the 90 min behavioral assessment (Figure 2A). Oral administration of 30 or 100 mg/kg LY544344 produced a significant decrease in spontaneous locomotor activity during the first 30 min of the behavioral assessment,  $F(5,35) = 3.67$ ,  $p < 0.005$ . One-way ANOVAs conducted at each timepoint revealed a significant difference between groups for each 5-min interval (all  $p$  values  $< 0.005$ ). Dunnett's  $t$ -tests indicated that rats administered 30 or 100 mg/kg LY544344 exhibited significantly decreased locomotor activity at each 5-min interval for the first 25 min of the assessment (all  $p$  values  $< 0.05$ ). In addition, rats administered 100 mg/kg LY544344 exhibited decreased spontaneous locomotor activity at the 30-min timepoint ( $p < 0.01$ ). No other significant differences were observed.

PCP evoked a significant increase in locomotor activity that was partially reversed by oral administration of LY354740 (Figure 2B), as indicated by a significant ANOVA,  $F(4,72) = 6.53$ ,  $p < 0.001$ . Post-hoc analysis (Dunnett's  $t$ -test) confirmed that rats administered 5 mg/kg PCP (veh/PCP group) demonstrated a significant increase in ambulatory movements, relative to vehicle controls (veh/veh group). However, oral administration of LY354740, at doses up 100 mg/kg, only partially reversed PCP-induced hyperlocomotion. Although rats administered 30 mg/kg and 100 mg/kg LY354740 did not differ significantly from the PCP group, these groups were not significantly different from the veh/veh group, indicating a partial reversal.

In contrast to the results of LY354740, PCP evoked a significant increase in locomotor activity, which was dose-dependently reversed LY544344 (Figure 2C),  $F(5,100) = 7.69$ ,  $p < 0.001$ . Specifically, 5 mg/kg PCP evoked a significant increase in locomotor activity, compared to the vehicle control group, while oral administration of LY544344 (30 and 100 mg/kg) significantly attenuated the PCP-induced hyperlocomotion by approximately 59% and 72%, respectively. Similar results were observed in measures of time at rest and head movements (data not shown, all  $p$  values  $< 0.001$ ).

### ***Stress-Induced Hyperthermia in DBA/2 Mice***

Table 2 details the effects of orally administered LY354740 and LY544344, and subcutaneously administered LY354740, on core body temperatures during the last 5-min block of the 60-min baseline period. Administration of LY354740 did not significantly affect core body temperatures during baseline, regardless of whether it was administered orally or subcutaneously ( $p$  values  $> 0.05$ ; Table 2). Oral administration of LY354740 produced a mild attenuation of stress-induced changes in core body temperature, relative to the last 5-min block of the baseline period (Figure 3A). However, this reduction was not statistically significant ( $p = 0.06$ ). For comparison purposes, the inset of Figure 3A shows that subcutaneous administration of 10 mg/kg LY354740 resulted in a significant attenuation of stress-induced hyperthermia,  $F(11,132) = 3.37$ ,  $p < 0.001$ . These latter results confirm our previous findings with LY354740 in a dose-response study (Rorick-Kehn et al., in press).

Oral administration of LY544344 produced a significant, dose-dependent reduction in stress-induced hyperthermia (Figure 3B;  $F(33,220) = 1.64$ ,  $p = 0.02$ ). Post-hoc comparisons confirmed that attenuation of the stress-induced hyperthermic response was significant in mice receiving 30 mg/kg. However, the 30 mg/kg dose of LY544344 also significantly increased core body temperatures during the baseline period,  $F(3,23) = 4.98$ ,  $p = 0.01$  (Table 2). Post-hoc tests confirmed that mice receiving an oral dose of 30 mg/kg had significantly higher pre-stress body temperatures, compared to the vehicle control group.

### ***Fear-Induced Suppression of Operant Behavior***

An initial experiment ( $n = 7$ ) indicated that subcutaneous administration of LY354740 produced a dose-dependent increase both in the number of lever presses during the 2-min CS period and in the suppression ratio, relative to the vehicle control day [ $F(3,18) = 6.64$ ,  $p < 0.005$  and  $F(3,18) = 9.47$ ,  $p < 0.001$ , respectively; Figure 4A]. A suppression ratio of 0 indicates a complete fear-induced suppression of operant responding during the CS period, whereas a suppression ratio of 0.5 indicates no suppression of operant behavior. Post-hoc tests confirmed

that the increased responding was significant at the 10 and 20 mg/kg doses for both measures (all  $p$  values  $< 0.05$ ). In addition, the total number of lever presses made during the 2-min pre-CS baseline period was decreased in rats receiving LY354740,  $F(3,18) = 5.78$ ,  $p < 0.01$ . Post-hoc tests confirmed that the attenuation of baseline responding was observed at all doses of LY354740.

In an additional experiment, oral administration of LY354740 had no significant effect on fear-induced suppression of operant behavior, or on the number of lever presses during the baseline and CS periods, as illustrated in Figure 4B ( $ps > 0.05$ ). In a follow-up experiment in the same rats, subcutaneous administration of 10 mg/kg LY354740 produced a significant increase in the number of lever presses during the CS period and in the suppression ratio, indicating anxiolytic effects [ $F(1,12) = 8.9$ ,  $p < 0.02$  and  $F(1,12) = 13.63$ ,  $p < 0.005$ , respectively; Figure 4B]. Also, the total number of lever presses during the 2-min pre-CS baseline period was decreased in rats receiving 10 mg/kg LY354740,  $F(1,12) = 12.72$ ,  $p < 0.005$ .

As illustrated in Figure 4C, oral administration of LY544344 significantly and dose-dependently increased the number of lever presses made during the CS period, as well as the suppression ratio [ $F(3,39) = 14.59$ ,  $p < 0.001$  and  $F(3,39) = 21.61$ ,  $p < 0.001$ , respectively]. Post-hoc tests indicated that the 30 mg/kg dose of LY544344 increased the number of lever presses made during the CS period, relative to the vehicle control. Post-hoc tests also determined that the 10 mg/kg and 30 mg/kg doses of LY544344 produced significantly higher suppression ratios than observed on the vehicle control day. That is, rats administered 10 and 30 mg/kg LY544344 demonstrated significantly decreased fear-induced suppression during the CS period, indicating anxiolytic effects. Additionally, LY544344 produced a reduction in the number of lever presses observed during the last 2 min of the baseline period, which was significant in rats administered 3 mg/kg [ $F(3,39) = 2.92$ ,  $p < 0.05$ ].



## Discussion

The present findings replicate and extend earlier reports that group II mGlu receptor agonism produces robust efficacy in animal behavioral models of psychosis and anxiety. In addition, our findings demonstrate the viability of a prodrug strategy in increasing oral bioavailability of LY354740. The paradigms used here are widely accepted *in vivo* paradigms that demonstrate predictive validity for clinical utility in psychiatric disorders. Although several studies indicate that LY354740 is active in animal models of psychosis and anxiety with minimal potential for side effects (Cartmell et al, 1999; Helton et al., 1998; Homayoun et al., 2005; Klodzinska et al., 1999; Moghaddam and Adams, 1998), it has low bioavailability following oral administration (~10%) due to poor gastrointestinal absorption (Johnson et al., 2002). Therefore, a prodrug approach was evaluated to increase oral bioavailability of the mGlu2/3 receptor agonist LY354740. Briefly, the prodrug LY544344 is transported from the intestinal lumen via PepT1 transporters, followed by rapid and extensive biotransformation into the parent compound LY354740 (Bueno et al., 2005). The resulting oral bioavailability of LY354740 in rats is approximately 85%, with no detectable prodrug levels 30-min post-administration (Bueno et al., 2005).

In the present pharmacokinetic experiments, oral administration of the prodrug LY544344 to rats resulted in approximately 10-fold greater exposure (relative to dose) to LY354740 in plasma, brain, and cerebrospinal fluid. The CNS penetration of LY354740 was relatively low, but is clearly driven by plasma concentration (Figure 1). These findings are consistent with previous reports that oral administration of the prodrug significantly increased intestinal uptake and subsequent bioavailability of the parent compound in rats (Bueno et al., 2005). In that study, LY544344 was completely bioconverted to the parent compound *in vivo* and activity in the fear-potentiated startle paradigm was increased significantly relative to LY354740. Moreover, the prodrug had no affinity for mGlu2 or mGlu3 receptors, suggesting that the anxiolytic effects resulted from bioconversion of the prodrug to the parent compound.

The current results support and extend previous findings by demonstrating that oral prodrug administration produced robust antipsychotic and anxiolytic effects in animal models of psychosis and anxiety.

PCP-induced hyperlocomotion was dose-dependently and completely inhibited in rats receiving oral administration of the mGlu2/3 prodrug LY544344 (30-100 mg/kg), whereas the mGlu2/3 agonist LY354740 did not fully reverse PCP-induced hyperlocomotion at doses up to 100 mg/kg (p.o.). Previous research indicated that LY354740 effectively reduced PCP-induced hyperlocomotion at doses as low as 10 mg/kg when administered intraperitoneally, and 0.1 mg/kg when administered subcutaneously (Cartmell et al., 1999; Moghaddam and Adams, 1998). Thus, the current results are consistent with evidence that poor gastrointestinal absorption of LY354740 results in low CNS concentrations (Johnson et al., 2002). In contrast to the parent compound, oral administration of LY544344 significantly reversed PCP-induced hyperlocomotion at doses as low as 30 mg/kg. These results, along with evidence that LY544344 is effectively converted into LY354740 *in vivo* (Bueno et al., 2005), indicate that the prodrug approach results in a marked improvement in exposure levels of the mGlu2/3 receptor agonist in the CNS.

The reversal of PCP-induced hyperlocomotion by LY544344 demonstrated here provides further support that activation of mGlu2/3 receptors produces antipsychotic effects in animal models of psychosis. Similar to all clinically active antipsychotics, LY544344 inhibited spontaneous locomotor activity at 30-100 mg/kg, which also effectively reversed PCP-induced hyperlocomotion (Arnt, 1995). However, at these doses, mGlu2/3 receptor agonists do not affect normal behavior, such as rotarod performance, suggesting decreased propensity for extrapyramidal side effects associated with such typical antipsychotics as haloperidol (Cartmell et al., 1999; Ogren and Goldstein, 1994). Indeed, LY354740 has been shown to reverse haloperidol-induced catalepsy in rats (Konieczny et al., 1998), suggesting that its effects are not attributable to nonspecific sedative effects.

Oral administration LY544344 and subcutaneous administration of LY354740 attenuated stress-induced hyperthermia in DBA/2 mice, with the prodrug producing anxiolytic effects at lower oral doses than the parent compound. The stress-induced hyperthermia model is a robust and reliable method of assessing anxiolytic efficacy, wherein reduction of stress-related increases in body temperature indicates anxiolytic properties (Bouwknicht and Paylor, 2002; Rorick-Kehn et al., in press; Spooren et al., 2002). Previous reports indicated that intraperitoneally administered LY354740 (3-10 mg/kg) and orally administered LY314582 (10 mg/kg; racemic mixture of LY354740) produced a dose-dependent reduction in stress-induced hyperthermia (Rorick-Kehn et al., in press; Spooren et al., 2002). In this experiment, although oral administration of LY354740 did not produce significant anxiolytic effects, subcutaneous administration of 10 mg/kg LY354740 significantly reduced stress-induced hyperthermia. In fact, this dose produced a greater attenuation than 30 mg/kg administered orally, reinforcing the necessity for improving bioavailability of this compound. In contrast to LY354740, orally administered LY544344 significantly reduced stress-related increases in body temperature at 30 mg/kg. Although pharmacokinetic data in the mouse are not available for these compounds, these behavioral results indicate greater bioavailability of LY354740 following oral administration of the prodrug.

At the highest dose tested, LY544344 increased body temperature during the baseline period, suggesting potential nonspecific effects on thermoregulatory mechanisms. The initial hyperthermia observed here was similar to that produced by some clinical anxiolytic compounds such as alprazolam and buspirone (Rorick-Kehn et al., in press). Nonetheless, that report indicated that drug effects on basal body temperature and stress-induced hyperthermia may be dissociable. Consistent with this conclusion, LY544344 significantly attenuated the stress response regardless of minor effects on basal body temperature. Overall, the present results confirm that mGlu2/3 agonists produce anxiolytic effects in an animal model of anxiety and

indicate that LY544344 effectively reduced stress-induced hyperthermia at a lower oral dose than LY354740.

Although oral administration of LY354740 did not significantly affect fear-induced suppression of operant responding, subcutaneously administered LY354740 (10 and 20 mg/kg) and orally administered LY544344 (10 and 30 mg/kg) produced significant anxiolytic effects. This model is a form of emotional conditioning in which ongoing behavior is suppressed in the presence of a signal predicting shock (CS). This conditioned fear is sensitive to the anxiolytic effects of diazepam, chlordiazepoxide, and ipsapirone, as these compounds alleviate fear-induced suppression of responding (Mirza et al., 2005; Stanhope and Dourish, 1996). Efficacious doses of subcutaneously administered LY354740 also produced a significant decrease in the number of responses during the baseline period, suggesting perhaps an effect on general motor or consummatory behavior. However, this reduction in baseline responding was mild and not likely to confound an anxiolytic interpretation. Consistent with this, LY354740 does not produce motor impairment in the rotarod or other tests of motor function (Cartmell et al., 1999; Helton et al., 1998; Konieczny et al., 1998), and similar effects on baseline responding were not observed at efficacious doses of LY544344. Regardless, if the compound were affecting general motor activity, one would expect to see an increase in operant suppression rather than the decrease that was observed here. In summary, both LY354740 (10-20 mg/kg, s.c.) and LY544344 (10-30 mg/kg, p.o.) produced anxiolytic effects in this model. These data extend previous reports of the functional efficacy of mGlu2/3 agonists in animal models of anxiety (Helton et al., 1998; Klodzinska et al., 1999; Tizzano et al., 2002) and fear-potentiated startle in humans (Grillon et al., 2003; for review, see Swanson et al., 2005).

The models used in these experiments are widely utilized to screen novel pharmacological agents for psychosis and anxiety, and they demonstrate predictive validity of clinical efficacy. The current results complement previous reports that mGlu2/3 receptor activation produces anxiolytic and antipsychotic effects in these and other animal models

(Helton et al., 1998; Homayoun et al., 2005; Klodzinska et al., 1999; Moghaddam and Adams, 1998; Schoepp et al., 1999; Schoepp and Marek, 2002; Tizzano et al., 2002). The reversal of the mGlu2/3 agonist effects by the selective mGlu2/3 receptor antagonist LY341495 in those studies indicates that the reported effects were mediated via mGlu2/3 receptor activation (Bueno et al., 2005; Cartmell et al., 1999). These receptors represent viable therapeutic targets because they exert a modulatory influence on glutamatergic tone via altering intracellular signaling cascades in key limbic and forebrain areas associated with anxiety, cognition, and higher executive function (Dube and Marshall, 1997; Ohishi et al., 1993a,b; Swanson et al., 2005). Thus, activation of mGlu2/3 receptors may provide a means to fine-tune the excessive glutamatergic activation associated with several psychiatric disorders without altering fast synaptic transmission or producing unwanted side effects, as observed with NMDA antagonists and benzodiazepines (Bergink et al., 2004; Gudex, 1991).

Therapeutic drugs that can be taken orally greatly improve both convenience for the patient and level of compliance because they do not require painful needlesticks or complicated delivery devices. Therefore, the possibility of improving the oral bioavailability of potentially beneficial drugs is of great interest. Growing preclinical literature indicates that group II mGlu receptor agonists, such as LY354740 and LY379268, may be effective novel treatments for several psychiatric disorders, including psychosis and anxiety (Swanson et al., 2005). Here, we demonstrated substantially improved oral bioavailability and efficacy of LY354740 using a prodrug strategy in various animal models of psychosis and anxiety. These data strongly suggest that the prodrug approach may be useful in the search for novel pharmacological treatments of many psychiatric disorders.

## References

- Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of  $D$ -amphetamine. *Eur J Pharmacol* **283**:55-62.
- Baptista MA, Martin-Fardon R and Weiss F (2004) Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. *J Neurosci* **24**:4723-4727.
- Bergink V, van Megen HJ and Westenberg HG (2004) Glutamate and anxiety. *Eur Neuropsychopharmacol* **14**:175-183.
- Bouwknicht JA and Paylor R (2002) Behavioral and physiological mouse assays for anxiety: A survey in nine mouse strains. *Behav Brain Res* **136**:489-501.
- Bueno AB, Collado I, de Dios A, Dominguez C, Martin JA, Martin LM, Martinez-Grau MA, Montero C, Pedregal C, Catlow J, Coffey DS, Clay MP, Dantzig AH, Lindstrom T, Monn JA, Jiang H, Schoepp DD, Stratford RE, Tabas LB, Tizzano JP, Wright RA and Herin MF (2005) Dipeptides as Effective Prodrugs of the Unnatural Amino Acid (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740), a Selective Group II Metabotropic Glutamate Receptor Agonist. *J Med Chem* **48**:5305-5320.
- Cartmell J, Monn JA and Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus  $D$ -amphetamine motor behaviors in rats. *J Pharmacol Exp Ther* **291**:161-170.

Cartmell J and Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. *J Neurochem* **75**:889-907.

Dube GR and Marshall KC (1997) Modulation of excitatory synaptic transmission in locus coeruleus by multiple presynaptic metabotropic glutamate receptors. *Neuroscience* **80**:511-521.

Feldman RS, Meyer JS and Quenzer LF (1997) Amino acid neurotransmitters and histamine, in *Principles of Neuropsychopharmacology* (Feldman RS, Meyer JS and Quenzer LF eds) pp 417-441, Sinauer Assoc., Inc., Sunderland, MA.

Grillon C, Cordova J, Levine LR and Morgan CA (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. *Psychopharmacology (Berl)* **168**:446-454.

Gudex C (1991) Adverse effects of benzodiazepines. *Soc Sci Med* **33**:587-596.

Helton DR, Tizzano JP, Monn JA, Schoepp DD and Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. *J Pharmacol Exp Ther* **284**:651-660.

Homayoun H, Jackson ME and Moghaddam B (2005) Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. *J Neurophysiol* **93**:1989-2001.

Johnson JT, Mattiuz EL, Chay SH, Herman JL, Wheeler WJ, Kassahun K, Swanson SP and

Phillips DL (2002) The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs. *Drug Metab Dispos* **30**:27-33.

Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P and Pilc A (1999) Potential anti-anxiety, anti-addictive effects of LY354740, a selective group II glutamate metabotropic receptor agonist in animal models. *Neuropharmacology* **38**:1831-1839.

Konieczny J, Ossowska K, Wolfarth S and Pilc A (1998) LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. *Naunyn-Schmiedeberg's Arch Pharmacol* **358**:500-502.

Mirza NR, Bright JL, Stanhope KJ, Wyatt A and Harrington NR (2005) Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? *Psychopharmacology (Berl)* **180**:159-168.

Moghaddam B (2002) Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. *Biol Psychiatry* **51**:775-787.

Moghaddam B and Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. *Science* **281**:1349-1352.

Ogren SO and Goldstein M (1994) Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. *Neuropsychopharmacology* **11**:167-177.



Ohishi H, Shigemoto R, Nakanishi S and Mizuno N (1993a) Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat.

*Neuroscience* **53**:1009-1018.

Ohishi H, Shigemoto R, Nakanishi S and Mizuno N (1993b) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. *J*

*Comp Neurol* **335**:252-266.

Parsons CG, Danysz W and Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. *Drug News Perspect* **11**:523-579.

Rorick-Kehn LM, Hart JC and McKinzie DL (in press) Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. *Psychopharmacology (Berl)*.

Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. *J Pharmacol Exp Ther* **299**:12-20.

Schoepp DD, Jane DE and Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. *Neuropharmacology* **38**:1431-1476.

Schoepp DD and Marek GJ (2002) Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? *Curr Drug Targets CNS Neurol Disord* **1**:215-225.

Spooren WPJM, Schoeffer P, Gasparini F, Kuhn R and Gentsch C (2002) Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using

classical and candidate anxiolytics (LY314582, MPEP, and NKP608). *Eur J Pharmacol* **435**:161-170.

Stanhope KJ and Dourish CT (1996) Effects of 5-HT<sub>1A</sub> receptor agonists, partial agonists and a silent antagonist on the performance of the conditioned emotional response test in the rat. *Psychopharmacology (Berl)* **128**:293-303.

Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA and Schoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. *Nat Rev Drug Discov* **4**:131-144.

Tizzano JP, Griffey KI and Schoepp DD (2002) The anxiolytic action of mGlu<sub>2/3</sub> receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. *Pharmacol Biochem Behav* **73**:367-374.

Vandergriff J and Rasmussen K (1999) The selective mGlu<sub>2/3</sub> receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. *Neuropharmacology* **38**:217-222.

## Footnotes

<sup>a</sup> Some portions of the data have been previously presented in poster form at the annual meeting of the International Behavioral Neuroscience Society (2004).

<sup>b</sup> **Author to whom reprint requests should be addressed:**

Dr. David McKinzie  
Neuroscience Discovery Research  
Eli Lilly and Company  
Lilly Corporate Center, DC0510  
Indianapolis, IN 46285 USA  
Email: dmckinzie@lilly.com

## Legends for Figures

**Figure 1.** Concentrations of LY354740 in plasma, CSF, and whole brain of Sprague Dawley rats following oral administration of LY544344 (10 mg/kg) or LY354740 (100 mg/kg). Values represent the mean ( $\pm$  SEM) of 3 samples per time point.

**Figure 2.** Spontaneous locomotor activity following oral administration of the mGlu2/3 receptor agonist LY354740 or the mGlu2/3 receptor agonist prodrug LY544344 (A) \*  $p < 0.05$  vs. vehicle group;  $n = 8/group$ . Effect of oral administration of various doses of LY354740 (B) or LY544344 (C) on phencyclidine (PCP)-induced (5 mg/kg, s.c.) increases in locomotor activity. Behaviors were monitored over a 60-min time period following injection of PCP or vehicle. Experimental compounds were administered 60 min prior to PCP injection. Values represent the mean ( $\pm$  SEM) number of ambulations ( $n = 9 - 15/group$ ). #  $p < 0.05$  vs. veh/veh control group. \*  $p < 0.05$  vs. veh/PCP group.



**Figure 3.** Time course of stress-induced hyperthermia following placement in a novel cage containing soiled shavings from a rat cage in male DBA/2 mice receiving oral administration of the mGlu2/3 receptor agonist LY354740 (A) or the mGlu2/3 prodrug LY544344 (B). Values represent changes in core body temperature in  $^{\circ}C$  ( $\pm$  SEM), relative to the pre-stress baseline period ( $n = 6 - 8/group$ ). For comparison purposes, the inset figure shows the mean ( $\pm$  SEM) stress-induced hyperthermia observed in mice subcutaneously administered vehicle (0.9% NaCl) or LY354740 (10 mg/kg). \*  $p < 0.05$  vs. vehicle group.

**Figure 4.** Initial experiment ( $n = 7$ ) evaluating the effect of subcutaneous administration of the mGlu2/3 receptor agonist LY354740 on fear-induced suppression of operant responding (A). Follow-up experiments examining the effect of oral versus subcutaneous administration of LY354740 (B) and oral administration of the mGlu2/3 prodrug LY544344 (C) on fear-induced suppression of operant responding ( $n = 14$ ). Values represent mean ( $\pm$  SEM) number of lever presses observed during the 2-min Baseline and CS periods (left panels), and fear-induced suppression ratios (right panels). A suppression ratio of 0 indicates complete suppression of

operant responding during the CS period, whereas a suppression ratio of 0.5 indicates no fear-induced suppression of operant behavior (i.e., anxiolytic effects). \*  $p < 0.05$  vs. vehicle group.

---

**Table 1. Plasma, brain, and CSF concentrations of LY354740 following an oral dose of LY354740 or LY544344.** Summary of LY354740 pharmacokinetic parameters in brain, plasma, and cerebrospinal fluid (CSF) of male Sprague-Dawley rats after a single oral administration of 100 mg/kg LY354740 or 10 mg/kg LY544344. Data are presented as the mean of 3 values per timepoint.  $C_{max}$  and  $AUC_{0-t}$  are rounded to no more than 3 significant figures.

	Compound Administered					
	LY354740 (100 mg/kg, p.o.)			LY544344 (10 mg/kg, p.o.)		
Structure						
	Plasma	Brain	CSF	Plasma	Brain	CSF
<b>LY354740 measured</b>						
$C_{max}$ (ng/ml)	2120	75.9	14.3	3300	84.4	24.2
$AUC_{0-t}$ (ng·hr/ml)	24300	6400	346	25700	7160	554
$t_{max}$ (hr)	3	24	3	0.5	12	3
$t_{1/2}$ (hr)	6.8	69	33	4.4	74	35
% Oral Bioavailability (F) of LY354740	10 <sup>a</sup>			85 <sup>b</sup>		

Abbreviations:  $C_{max}$  = maximal concentration;  $AUC_{0-t}$  = area under the concentration versus time curve from 0 to the last quantifiable timepoint;  $t_{max}$  = time to  $C_{max}$ ;  $t_{1/2}$  = half-life.


<sup>a</sup> From Johnson et al. (2002); bioavailability following 30 mg/kg (p.o.) dose of LY354740.

<sup>b</sup> From Bueno et al. (2005); bioavailability following 5 mg/kg (p.o.) dose of LY544344.

**Table 2. Effects of the mGlu2/3 receptor agonist LY354740 or the mGlu2/3 prodrug LY544344 on baseline body temperature (in ° C) in the stress-induced hyperthermia model.** Data are presented as the mean ( $\pm$  SEM) pre-stress core body temperature, measured at the end of the 60-min baseline period (i.e., prior to presentation of the stressor), in male DBA/2 mice.




<b>Compound</b>	<b>Dose (mg/kg)</b>	<b>N</b>	<b>Pre-Stress Body Temp (SEM)</b>
LY354740 (p.o.)	0	8	36.20 (0.22)
	3	7	36.23 (0.31)
	10	6	36.09 (0.18)
	30	7	36.30 (0.34)
LY544344 (p.o.)	0	6	36.02 (0.28)
	3	6	36.92 (0.18)
	10	6	36.60 (0.14)
	30	6	37.45 (0.15)*
LY354740 (s.c.)	0	7	36.41 (0.23)
	10	7	36.58 (0.40)

\* Significant difference from vehicle group ( $p < 0.05$ ).




Downloaded from journals.ascp.org on April 18, 2024








**A****B****C**

# A LY354740



# B LY544344



**A****LY354740****B****LY354740****C****LY544344**